On August 31, 2022 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September (Press release, Decibel Therapeutics, AUG 31, 2022, View Source [SID1234618805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 17th Annual BioPharma Conference:

Rare disease panel on Wednesday, September 7, 2022 at 11:20 a.m. ET in Boston, MA.
H.C. Wainwright 24th Annual Global Investment Conference:

Virtual presentation available for on demand viewing starting on Monday, September 12, 2022 at 7:00 a.m. ET
Baird 2022 Global Healthcare Conference:

Fireside chat on Tuesday, September 13, 2022 at 3:10 p.m. ET in New York, NY.
Cantor Cell & Genetic Medicines Conference:

Panel titled, "Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place," on Thursday, September 15, 2022 at 8:00 a.m. ET in New York, NY.
Webcasts of the Citi, H.C. Wainwright and Baird events may be accessed by visiting the Investors section of the Decibel Therapeutics website at View Source An archived replay of the webcasts will be available on the Company’s website for approximately 90 days following these events.

On August 31, 2022 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that it will participate in three upcoming investor conferences (Press release, Arvinas, AUG 31, 2022, View Source [SID1234618804]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 17th Annual BioPharma Conference: Thursday, September 8 at 1:00 p.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

2022 Wells Fargo Healthcare Conference: Friday, September 9 at 9:45 a.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

Morgan Stanley 20th Annual Global Healthcare Conference: Monday, September 12 at 11:05 a.m. ET. Ian Taylor, Ph.D., chief scientific officer, and Randy Teel, senior vice president, corporate and business development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

On August 31, 2022 Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, reported that it will be participating in four upcoming investor conferences (Press release, Akoya Biosciences, AUG 31, 2022, View Source [SID1234618803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference (New York, NY)
Presentation on Monday, September 12th at 11.30 AM ET
Morgan Stanley 20th Annual Global Healthcare Conference (New York, NY)
Fireside chat on Wednesday, September 14th at 8:35 AM ET
Capital One Spatial Biology & Proteomics Summit (Virtual)
Spatial Biology & Single Cell panel discussion on Wednesday, September 28th at 10:15 AM ET
Executive panel discussion on Wednesday, September 28th at 1:00 PM ET
Bank of America Healthcare Innovation Forum (Virtual)
Spatial Biology & Single Cell panel discussion on Thursday, September 29th at 11 AM ET
A live and archived webcast of the Morgan Stanley Global Healthcare Conference will be available on the "Investors" section of the Akoya website at View Source

On August 31, 2022 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, reported that members of the management team will participate in the following upcoming investor conferences (Press release, 2seventy bio, AUG 31, 2022, View Source [SID1234618802]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

17th Annual Citi BioPharma Conference, "Cell Therapy Part 1" panel on Wednesday, September 7, 2022 at 9:40am ET in Boston, MA
2022 Morgan Stanley Global Healthcare Conference, fireside chat on Wednesday, September 14, 2022 at 11:45am ET in New York, NY
Live webcasts will be available via the Investors and Media section of 2seventy bio’s website at View Source A replay will be archived on 2seventy bio’s site for 30 days following the event.

On August 31, 2022 SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, reported a regulatory update on emactuzumab, in development for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases (Press release, SynOx Therapeutics, AUG 31, 2022, View Source [SID1234618800]). The European Medicines Agency (EMA) has designated emactuzumab as an orphan medicinal product in the indication of TGCT for both localized and diffuse types of the disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TGCT is a rare, chronically debilitating disease affecting the synovium, tendon sheaths and bursa membranes, primarily of knee, hip and ankle joints. It causes loss of function of the affected joints, pain, stiffness and limited range of motion. TGCT has an incidence of 43 cases per million patient years, of which 4 per million patient years relate to diffuse TGCT1. No systemic treatments have been approved for TGCT in the EU. Most patients receive surgical intervention, with a post-surgery recurrence rate of up to 50%2.

Emactuzumab is a novel monoclonal antibody inhibiting CSF-1R that offers a short course of treatment. Phase I/II studies indicated good tolerability and a manageable safety profile and substantial preliminary efficacy in TGCT patients with rapid, robust tumour reduction and durable response.

SynOx is planning a phase III trial (TANGENT) to assess the efficacy and safety of emactuzumab in patients with localized or diffuse TGCT where surgical removal of the tumour is not viewed as an option. More details can be found on www.clinicaltrials.gov (with trial identifier NCT05417789) and at www.tangentstudy.com.

Ray Barlow, Chief Executive Officer of SynOx, said: "We have made significant progress in the development of emactuzamab in TGCT in the last 12 months. The positive opinion regarding the orphan drug designation marks an important step in SynOx’s continuing journey to provide a potential therapeutic option for patients with this debilitating disease. We are now recruiting patients on to our phase III registrational trial (TANGENT) and look forward to providing an update on progress in the near future."